Serine Protein Kinase ATM Ataxia Telangiectasia Mutated or ATM or EC 2.7.11.1 Pipeline Review, H2 2018
Summary
Serine Protein Kinase ATM Ataxia Telangiectasia Mutated or ATM or EC 2.7.11.1 pipeline Target constitutes close to 7 molecules. Out of which approximately 6 molecules are developed by companies and remaining by the universities/institutes. The latest report Serine Protein Kinase ATM Pipeline Review, H2 2018, outlays comprehensive information on the Serine Protein Kinase ATM Ataxia Telangiectasia Mutated or ATM or EC 2.7.11.1 targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action MoA, route of administration RoA and molecule type.
Serine Protein Kinase ATM Ataxia Telangiectasia Mutated or ATM or EC 2.7.11.1 Serine Protein Kinase ATM is a serine/threonine protein kinase. It activates checkpoint signaling upon double strand breaks DSBs, apoptosis and genotoxic stresses such as ionizing ultraviolet A light UVA, thereby acting as a DNA damage sensor. It plays a role in replicationdependent histone mRNA degradation. It binds DNA ends. The molecules developed by companies in Phase I, Preclinical and Discovery stages are 3, 2 and 1 respectively.
Similarly, the universities portfolio in Preclinical stages comprises 1 molecules, respectively. Report covers products from therapy areas Oncology and Ophthalmology which include indications Adenocarcinoma, Colorectal Cancer, Colorectal Tumor, Gastric Cancer, Glioblastoma Multiforme GBM, Head And Neck Cancer, Head And Neck Cancer Squamous Cell Carcinoma, Herpetic Keratitis, Human Papillomavirus HPV Associated Cancer, Lymphoma, Multiple Myeloma Kahler Disease, Solid Tumor and Squamous Cell Carcinoma.
Furthermore, this report also reviews key players involved in Serine Protein Kinase ATM Ataxia Telangiectasia Mutated or ATM or EC 2.7.11.1 targeted therapeutics development with respective active and dormant or discontinued projects. Driven by data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industryspecific third party sources.
Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.
Scope
The report provides a snapshot of the global therapeutic landscape for Serine Protein Kinase ATM Ataxia Telangiectasia Mutated or ATM or EC 2.7.11.1
The report reviews Serine Protein Kinase ATM Ataxia Telangiectasia Mutated or ATM or EC 2.7.11.1 targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industryspecific sources
The report covers pipeline products based on various stages of development ranging from preregistration till discovery and undisclosed stages
The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, RD brief, licensing and collaboration details other developmental activities
The report reviews key players involved in Serine Protein Kinase ATM Ataxia Telangiectasia Mutated or ATM or EC 2.7.11.1 targeted therapeutics and enlists all their major and minor projects
The report assesses Serine Protein Kinase ATM Ataxia Telangiectasia Mutated or ATM or EC 2.7.11.1 targeted therapeutics based on mechanism of action MoA, route of administration RoA and molecule type
The report summarizes all the dormant and discontinued pipeline projects
The report reviews latest news and deals related to Serine Protein Kinase ATM Ataxia Telangiectasia Mutated or ATM or EC 2.7.11.1 targeted therapeutics
Reasons to buy
Gain strategically significant competitor information, analysis, and insights to formulate effective RD strategies
Identify emerging players with potentially strong product portfolio and create effective counterstrategies to gain competitive advantage
Identify and understand the targeted therapy areas and indications for Serine Protein Kinase ATM Ataxia Telangiectasia Mutated or ATM or EC 2.7.11.1Identify the use of drugs for target identification and drug repurposing
Identify potential new clients or partners in the target demographic
Develop strategic initiatives by understanding the focus areas of leading companies
Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
Devise corrective measures for pipeline projects by understanding Serine Protein Kinase ATM Ataxia Telangiectasia Mutated or ATM or EC 2.7.11.1 development landscape
Develop and design inlicensing and outlicensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope